SERPINB11 Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary

In Vivo. 2021 Sep-Oct;35(5):2647-2653. doi: 10.21873/invivo.12547.

Abstract

Background/aim: To evaluate the role of serine protease inhibitor B11 (SERPINB11) expression as a prognostic biomarker in high-grade serous carcinoma (HGSC) and clear cell carcinoma of the ovary (CCC).

Materials and methods: We obtained tumor tissues from patients with HGSC (n=145) and CCC (n=59). We evaluated immunohistochemically the expression of SERPINB11 and investigated whether SERPINB11 expression affects platinum-resistance and the prognosis of HGSC and CCC.

Results: High expression of SERPINB11 was more common in CCC than in HGSC (57.6% vs. 28.3%; p<0.01), and SEPRINB11 expression did not correlate with platinum-resistance of HGSC and CCC. High expression of SERPINB11 was associated with worse progression-free survival and overall survival with marginal significance in HGSC; no relation between SERPINB11 expression and the prognosis of CCC was found.

Conclusion: SERPINB11 expression maybe a prognostic biomarker for HGSC.

Keywords: High-grade serous; SERPINB11; clear cell; ovarian cancer; prognosis.

MeSH terms

  • Adenocarcinoma, Clear Cell* / genetics
  • Biomarkers, Tumor / genetics
  • Female
  • Humans
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / genetics
  • Prognosis
  • Serine Proteinase Inhibitors
  • Serpins* / genetics

Substances

  • Biomarkers, Tumor
  • SERPINB11 protein, human
  • Serine Proteinase Inhibitors
  • Serpins